Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.
The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.
Rani Therapeutics (Nasdaq: RANI) presenterà dati preclinici sull'semaglutide orale (RT-116) somministrato tramite la capsula RaniPill® a ObesityWeek® 2025.
L'abstract indica che lo semaglutide orale nei cani era bioequivalente alle iniezioni sottocutanee e ha provocato una perdita di peso simile. Il poster (n. 647) sarà presentato da Kyle Horlen, DVM, VP dello Sviluppo Non Clinico, il 6 novembre 2025, 14:30–15:30 ET al Georgia World Congress Center, Exhibit Hall A1; la riunione è dal 4 al 7 novembre 2025 e prevede partecipazione virtuale.
Rani Therapeutics (Nasdaq: RANI) presentará datos preclínicos sobre semaglutida oral (RT-116) administrada mediante la cápsula RaniPill® en ObesityWeek® 2025.
El resumen indica que la semaglutida oral en perros fue bioequivalente a las inyecciones subcutáneas y produjo una pérdida de peso similar. El póster (No. 647) será presentado por Kyle Horlen, DVM, VP de Desarrollo No Clínico, el 6 de noviembre de 2025, 2:30–3:30 p.m. ET en el Georgia World Congress Center, Exhibit Hall A1; la reunión es del 4 al 7 de noviembre de 2025 e incluye participación virtual.
Rani Therapeutics (나스닥: RANI)은 ObesityWeek® 2025에서 RaniPill® 캡슐을 통해 투여된 구강 세마글루타이드를 다루는 전임상 데이터를 발표합니다.
초록은 개에서 구강 세마글루타이드가 피하 주사와 생체이동성이 동일했고 유사한 체중 감소를 초래했다고 보고합니다. 포스터(번호 647)는 Kyle Horlen, DVM, 비임상 개발 부사장이 2025년 11월 6일, 동부 표준시 14:30–15:30에 조지아 월드 컨굼스 센터의 Exhibit Hall A1에서 발표합니다. 회의는 2025년 11월 4–7일 동안 진행되며 가상 참여가 포함됩니다.
Rani Therapeutics (Nasdaq : RANI) présentera des données précliniques sur la semaglutide orale (RT-116) administrée via la capsule RaniPill® lors d'ObesityWeek® 2025.
L'abstract indique que la semaglutide orale chez le chien était bioéquivalente aux injections sous-cutanées et a entraîné une perte de poids similaire. Le poster (No. 647) sera présenté par Kyle Horlen, DVM, VP du Développement Non Clinique, le 6 novembre 2025, 14h30–15h30 ET au Georgia World Congress Center, Exhibit Hall A1; la réunion se tient du 4 au 7 novembre 2025 et prévoit une participation virtuelle.
Rani Therapeutics (Nasdaq: RANI) wirdpräklinische Daten zu oralem Semaglutid (RT-116), verabreicht über die RaniPill®-Kapsel, auf der ObesityWeek® 2025 vorstellen.
Der Abstract berichtet, dass oral Semaglutid bei Hunden biöequivalent zu subkutanen Injektionen war und einen ähnlichen Gewichtsverlust verursachte. Das Poster (Nr. 647) wird von Kyle Horlen, DVM, VP für Nichtklinische Entwicklung, am 6. November 2025, 14:30–15:30 Uhr ET im Georgia World Congress Center, Exhibit Hall A1, vorgestellt; die Veranstaltung findet vom 4. bis 7. November 2025 statt und schließt eine virtuelle Teilnahme ein.
Rani Therapeutics (ناسداك: RANI) ستعرض بيانات ما قبل السريرية عن السيماغلوتايد الفموي (RT-116) المقدم عبر كبسولة RaniPill® في ObesityWeek® 2025.
تشير الخلاصة إلى أن السيماغلوتايد الفموي عند الكلاب كان مكافئاً حيوياً للحقن تحت الجلد وأدى إلى فقدان وزن مشابه. سيتم تقديم الملصق (الرقم 647) بواسطة كايل هورلن، DVM، نائب رئيس التطوير غير السريري، في 6 نوفمبر 2025، من 2:30–3:30 م بالتوقيت الشرقي في Georgia World Congress Center، Exhibit Hall A1؛ الاجتماع من 4 إلى 7 نوفمبر 2025 ويتضمن المشاركة الافتراضية.
- None.
- None.
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia.
Details of the presentation are as follows:
Abstract Title: Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss
Session Type: Poster Session
Poster Number: 647
Location: Georgia World Congress Center, Exhibit Hall A1
Session Date & Time: November 6, 2025 from 2:30 pm – 3:30 pm E.T.
Presenting Author: Kyle Horlen, DVM, VP of Nonclinical Development
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
When will Rani Therapeutics present the RT-116 preclinical poster at ObesityWeek 2025 (RANI)?
What did Rani report about oral semaglutide (RT-116) in the ObesityWeek 2025 abstract?
Where can attendees find Rani Therapeutics’ poster at ObesityWeek 2025 (RANI)?
Who is presenting Rani Therapeutics’ preclinical data on RT-116 at ObesityWeek 2025 (RANI)?
Will Rani Therapeutics’ ObesityWeek 2025 presentation be available virtually?
